| Autor: |
Cintra, OAL, Feitosa, MAI, Silva, K Z, Paula, F E, Silva, M L, Bueno, CDF, Ansarah-Sobrinho, C, Paiva, T M, Arruda, E |
| Zdroj: |
Pediatric Research; November 2006, Vol. 60 Issue: 5 p637-637, 1p |
| Abstrakt: |
Background: Influenzavirus (Flu) is associated with high morbidity in children less than 24-mo old, with high rates of hospitalization. Recommendation for annual influenza vaccination has been extended to this age group in the USA.Objective: We evaluated the proportion of Flu-attributable disease in children younger than 2 years, admitted to a tertiary care hospital for LRTI during the 2004 influenza seasonal outbreak in southeast Brazil.Methods: All samples submitted for respiratory virus detection were tested for Flu by immunofluorescence and/or RT-PCR. Influenza positive samples were used for viral isolation and identification. Patient records were reviewed for length of hospital stay (LOS), need for oxygen supplementation (OS) and clinical diagnosis.Results: From March to May 2004, 159 samples were collected and 17 (10.7%) were positive for influenza A. Influenza virus was isolated from 6 samples, all of them A/Korea (H3N2). Of the 17 positive samples, 8 (47%) were obtained in April. Patient records were available for review in 12 cases (7 boys). Of these, 10 (83%) were < 9-mo old and 5 (42%) were 6- to 8-mo old. Bronchiolitis was present in 50%(6/12) and pneumonia in 33% (4/12). LOS ranged from 2 to 10 days and 58% had > 6 days. OS was required by 58% (7/12) of the patients and 71% (5/7) required O2 for 6 or more days. Bronchodilators and antibiotics were the two most frequent treatments used (92% and 42%, respectively).Conclusions: During this outbreak in a subtropical region of Brazil, influenza associated disease represented 10.7% of all hospitalizations in children less than 24 months of age with LRTI, and the associated morbidity was responsible for prolonged LOS and requirement for OS. The impact of influenza-associated disease on pediatric hospitalization could be reduced by vaccination in this age group.Financial Support: FAPESP, CNPq and Sanofi -Pasteur |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
